Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00986479 · ClinicalTrials.gov registry record · Phase 2
This is a Study to Determine the Antidepressant Effects of AZD6765
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00986479: Completed Phase 2 study, sponsored by AstraZeneca.
NCT00986479 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00986479, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.
Primary Outcome
Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item instrument used for the evaluation of depressive symptoms. Each item is rated on a scale of 0 to 6 (with higher scores indicating more severe depression). The individual item scores are added together to form a total score, ranging between 0 and 60. 0 is considered the best score, 60 the worst.
Interventions
- DRUG AZD6765
- DRUG Placebo to AZD6765
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT00986479 record still lists
NCT00986479 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which AZD6765 is the first listed.
NCT00986479 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00986479 about?
NCT00986479 is a clinical study titled "This is a Study to Determine the Antidepressant Effects of AZD6765". The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.
What is the current status of trial NCT00986479?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2009-12. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00986479?
The interventions under investigation include: AZD6765 (DRUG), Placebo to AZD6765 (DRUG).
Who is sponsoring clinical trial NCT00986479?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00986479's enrollment target sits among peer trials
22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia